GSK, CureVac Expand Licensing Agreement
By Anthony O. Goriainoff
GSK said that under a new licensing deal with biotech company CureVac it will acquire full rights to develop, manufacture and commercialize internationally messenger RNA, or mRNA, candidate vaccines for influenza and Covid-19.
U.K. pharmaceutical company GSK said the restructured collaboration allows both companies to prioritize their investments and focus their respective mRNA development activities.
mRNA vaccines are those which use messenger ribonucleic acid instead of an actual bacteria or virus in the production process, and were widely used to combat Covid-19.
CureVac will get a 400 million euros ($429.9 million) upfront payment and is eligible to up to a further EUR1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties in the high to low teens million range. It will also retain exclusive rights to the additional undisclosed and preclinically validated infectious disease targets from the prior collaboration.
GSK said that all financial considerations stemming from their prior collaboration deal were replaced by the new licensing agreement. It added that the new agreement's completion remained subject to some antitrust and regulatory approvals as well as the customary closing conditions.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
July 03, 2024 02:50 ET (06:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks